Introduction
Lung cancer remains a major public health problem in most industrialized countries [1, 2] . Most lung cancers are attributable to cigarette smoking, and primary prevention is a continuing priority. Increasingly, lung cancer is now occurring in ex-smokers [3] . Additional preventive strategies are needed to reduce the mortality from this epidemic. Whereas early lung cancer screening trials have yielded disappointing results, more sensitive screening techniques have been developed, including biomarkers and low-dose CT. Research progress has been most rapid with radiological approaches and randomized controlled trials (RCTs) of CT screening are currently being conducted. In the interim. debate continues over the potential cost effectiveness of CT screening and its appropriate use in contemporary clinical practice.
Screening with plain chest radiography
The efficacy of chest radiography screening for lung cancer continues to be debated [4•,5•,6••]. A systematic review of controlled trials of lung cancer screening reviewed the evidence from seven trials [6••,7] . In all studies, the control group received some type of screening. Five studies effectively compared more frequent chest radiography screening with less frequent chest radiography screening [8] [9] [10] [11] [12] . In the meta-analysis, more frequent chest radiograph screening was associated with an 11% relative increase in mortality from lung cancer (relative risk 1.11, 95% confidence interval 1.00-1.23) [6••,8,10-12] . Although the possibility of harm from screening exists, the finding of increased mortality in the frequently screened group could be due to inadequate randomization resulting in population heterogeneity between the control and intervention groups. However, the trend to increased mortality was seen in all studies reviewed. Another alternative explanation is that lung cancer deaths could have been undetected or unreported in the control group and that some deaths in the intervention group due to comorbid disease were misclassified as death due to lung cancer [13, 14] . None of the trials reported have adequately assessed the efficacy of annual chest radiograph screening compared with no screening, and this issue is currently being evaluated in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial [15] . However, this trial has already attracted criticism for a failure to enroll high-risk groups [16] . Current methods of evaluation and management of small nodules detected by CT require validation in long-term studies. Issues such as the frequency and duration of follow-up are yet to be resolved. Previous reports based on chest radiography show that some lung cancers can appear stable for many years before growth is detected at serial follow-up [31, 32] . Furthermore, slow growth of a primary tumor does not preclude metastatic spread [33] . Growth can be more accurately detected by CT than by chest radiography [28] . However, even with serial CT examinations, it is likely that follow-up of more than 2 years will be necessary for some nodules [34•]. The medicolegal implications of delayed diagnosis in this setting are untested but could be similar to the experience reported for breast cancer [35] . In the future, biomarkers, in addition to growth patterns, could be used to help distinguish between benign, premalignant, and malignant lesions, but the feasibility and validity of such an approach requires further evaluation [36•].
Although some experts have questioned the role of RCTs in the setting of screening evaluation, they are generally considered to be the gold standard [37, 38] . Several RCTs of CT screening are being planned or are in progress [39•]. The National Lung Screening Trial is a National Cancer Institute-sponsored RCT comparing annual chest radiography with annual spiral low-dose CT for 3 years. This trial has enrolled nearly 50,000 exsmokers and current heavy smokers across multiple centers in the United States. Enrollment closed in February 2004, and participants will be followed up until 2009 [39a]. A further RCT will be conducted in the Netherlands and Leuven (Belgium) [40] .
Cost-effectiveness of computed tomography screening for lung cancer
In a cost-effectiveness analysis based on the results of the Early Lung Cancer Action Project, an incremental cost-effectiveness ratio of $2500 per life year saved for a single baseline low-dose CT scan in high-risk individuals was reported [41•]. These results differ markedly from those of another cost-effectiveness analysis in which relevant probabilities were based on the weighted average of several CT studies and quality-adjusted life years were assessed in addition to life years saved [42••] . In this model, current smokers in a hypothetical cohort were considered who were offered annual low-dose CT screening compared with a cohort not offered screening. The model predicted, over a 20-year period, a 13% reduction in lung cancer-specific mortality, assuming a 50% stage shift. The incremental cost effectiveness ratio per quality-adjusted life year was $116,300 [42••] . This analysis was criticized because of the large number of variables included, some of which were estimated from limited data [43] . The disparity between the results of these analyses and others is a reflection of the different assumptions used in the models and particularly the level of uncertainty in the estimates of screening efficacy. Future analyses based on the results of RCTs are likely to yield more reliable results. Identification of very high-risk groups is likely to be the most cost-effective screening strategy [ Furthermore, comorbid conditions that contraindicate surgery could also impair host defenses against the tumor and increase lung cancer mortality [58] . Because CT can detect smaller lesions than chest radiography, the potential for overdiagnosis is greater. In a review of coronial autopsies, approximately 1 in 300 decedents going to autopsy had lung cancer detected that was undetected during life and did not contribute to death [59] . However, although incidental cancers were uncommon, the median tumor size of incidental lesions was 3 cm (range 1-10 cm), and it is likely that routine autopsies may not detect many of the smaller cancers currently detectable by CT [59,60].
The natural history of lung cancer: implications for early detection and treatment
The tendency for CT screening to detect predominantly adenocarcinomas may be viewed favorably, given that this is now the predominant histologic type of lung cancer in many industrialized countries [61]. However, it is possible that the benefits of early detection and treatment could differ between different histologic groups. Squamous cell carcinomas tend to be centrally located and grow more rapidly than adenocarcinomas but are less likely to metastasize to distant sites after surgery for localized disease [62] . Furthermore, lymph node micrometastases are more common in small peripheral adenocarcinomas, compared with small peripheral squamous cell carcinomas, being demonstrable in 36% of adenocarcinomas 1 cm or less in size, but absent or uncommon in squamous cell carcinomas of 2 cm or less [63] . On the basis of tumor doubling times, it has been estimated that an adenocarcinoma takes an average of 13.2 years to reach 1 cm and a further 2.2 years to reach 3 cm [64] . It is not surprising that smaller tumors might demonstrate prolonged disease-free survival when measured from the point of diagnosis, because it is likely that many will have been detected at an earlier point in their development [65•] . The question remains whether the natural history will be altered by early detection and intervention, particularly given the long duration of adenocarcinoma prior to detection with current screening methods.
The benefit of screening is dependent on having effective therapy for early-stage disease. However, there have been no reported RCTs of surgery or radiotherapy for stage I or stage II non-small cell lung cancers that have included an untreated control group [58, 66] . In one early study, pneumonectomy or lobectomy improved survival at 4 years in patients with squamous cell carcinoma compared with radiotherapy [67] . Whereas observational data support the role of surgery for early-stage non-small cell lung cancer, the magnitude of any benefit and the types of patients who benefit most is unclear. Some experts have postulated that non-small cell lung cancer is a biologically variable disease in which anatomic staging identifies more indolent tumors that are likely to have a more favorable clinical course regardless of the intervention [58, 64] . This hypothesis warrants further consideration in relation to adenocarcinoma, which is particularly heterogeneous, with a wide range of doubling times reported [51, 68] . In one study of slow-growing tumors, survival in individuals with adenocarcinoma correlated well with tumor doubling time, even in those with resected tumors [50] . Lung cancer studies of gene expression arrays have identified different subclasses of adenocarcinoma with particular patterns of gene expression that correlate with survival [69, 70] . What remains unclear is whether subclasses with different gene expression patterns have arisen from different precursor cells or whether the subclass with a more favorable gene expression pattern is simply at an intermediate point in the development to the invasive phenotype [70] .
Alternative approaches
Although standard sputum cytology lacks sensitivity, new methods of sputum analysis have now been devel- Molecular approaches are likely to be the most effective early detection method because they can lead to the detection of preinvasive changes and therefore provide the opportunity for intervention at a much earlier point in the development of cancer. Coupled with noninvasive chemoprevention, molecular approaches could be more widely applicable [72] . In the future, noninvasive and well-tolerated chemoprevention could have a role in both primary and secondary prevention [75••] . Molecular targeted agents are currently being evaluated in clinical trials to assess their ability to prevent the appearance and progression of premalignant lesions in former or current smokers with a history of smoking-related cancer [76•] .
Conclusion
Low dose spiral CT screening is a sensitive screening technique for early-stage lung cancer, particularly adenocarcinoma. However there is insufficient evidence to support screening in contemporary practice. In the future, the results of RCTs will better inform us about whether the early detection and treatment of cancers detected by CT leads to a reduction in mortality and if the potential benefits of screening outweigh the harms associated with false positive diagnoses or overdiagnosis. If CT screening has only a small impact on lung cancer mortality then cost effectiveness will most likely be unfavorable in the context of current diagnostic and therapeutic approaches. Alternative approaches to secondary prevention such as screening with biomarkers, autofluorescence bronchoscopy and chemoprevention await further development and evaluation in prospective trials.
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